Table 3.
Association between treatment response (PSA ≤0.2 ng/ml) at last follow-up and possibly interacting variables (logistic regression analysis, all patients)
| Association between treatment response and | p-Valuea | p-Valueb |
|---|---|---|
| ADT at time of RT | 0.104 | 0.131 |
| PRE-RT PSA ≤/> 0.5 ng/ml | 0.226 | 0.188 |
| Gleason Score (6–7 vs. 8–9) | 0.129 | 0.791 |
| pT stage | 0.104 | 0.195 |
| pN stage | 0.341 | 0.908 |
| Surgical margins | 0.833 | 0.609 |
| PSA after RT ≤ 0.1 ng/ml | 0.008 | 0.007 |
| PSMA PET result (Negative or fossa recurrence only vs. lymph node recurrence) |
0.623 | 0.999 |
| PSMA PET result (positive vs. negative) |
0.263 | 0.693 |
| Dose escalation prostate fossa ≤66.6Gy vs. >66Gy | 0.324 | 0.122 |
| Dose escalation pelvic lymph nodes ≤50.4Gy vs. >50.4Gy | 0.371 | 0.999 |
| RT indication (biochemical recurrence vs. biochemical persistence) | 0.026 | 0.211 |
PSA prostate specific antigen, ADT androgen deprivation therapy, PRE-RT PSA PSA pre-radiotherapy, RT radiotherapy
aunivariate and bmultivariate binary logistic regression analysis
*p < 0.05 statistically significant